美国风湿病学会儿童SARS-CoV-2相关多系统炎症综合征与儿童COVID-19高炎症临床指南(第二版)
该指南由美国风湿病学会工作组制定,针对儿童SARS-CoV-2感染相关的多系统炎症综合征(MIS-C)及儿童COVID-19急性期高炎症的管理提供推荐。
要点
- 指南涵盖MIS-C的诊断路径与初始免疫调节治疗推荐。
- 推荐同样适用于儿童COVID-19急性感染期的高炎症状态。
- 共识采用9分制评估适当性,仅适当且中/高共识的声明获批。
核心结论
- 该指南为MIS-C及儿童COVID-19高炎症的管理提供基于现有证据与专家意见的推荐,并将随证据更新而修订。
研究设计与样本
- 工作组由9名儿童风湿病学家、2名成人风湿病学家、2名儿童心脏病学家、2名儿童感染病专家和1名儿童重症监护医生组成。
- 通过改良Delphi流程(匿名投票与网络研讨会讨论)达成共识,采用9分制评估声明适当性。
主要发现
- 第一版指南于2020年6月获批,包含40条最终指导声明及描述MIS-C诊断路径的流程图。
关键数值与推荐
- 适当性评分:中位数1-3为不适当,4-6为不确定,7-9为适当。
- 共识水平根据投票离散程度分为低、中、高;仅适当且中或高共识的声明获批。
临床怎么用
- 临床可参照指南中的流程图进行MIS-C的诊断评估及初始免疫调节治疗决策。
局限性
- 指南反映当前可获得的证据与专家意见,需随证据更新而修订。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To provide guidance on the management of Multisystem Inflammatory Syndrome in Children (MIS-C), a condition characterized by fever, inflammation, and multiorgan dysfunction that manifests late in the course of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. Recommendations are also provided for children with hyperinflammation during coronavirus disease 2019 (COVID-19), the acute, infectious phase of SARS-CoV-2 infection. METHODS: The Task Force was composed of 9 pediatric rheumatologists and 2 adult rheumatologists, 2 pediatric cardiologists, 2 pediatric infectious disease specialists, and 1 pediatric critical care physician. Preliminary statements addressing clinical questions related to MIS-C and hyperinflammation in COVID-19 were developed based on evidence reports. Consensus was built through a modified Delphi process that involved anonymous voting and webinar discussion. A 9-point scale was used to determine the appropriateness of each statement (median scores of 1-3 for inappropriate, 4-6 for uncertain, and 7-9 for appropriate). Consensus was rated as low, moderate, or high based on dispersion of the votes. Approved guidance statements were those that were classified as appropriate with moderate or high levels of consensus, which were prespecified before voting. RESULTS: The first version of the guidance was approved in June 2020, and consisted of 40 final guidance statements accompanied by a flow diagram depicting the diagnostic pathway for MIS-C. The document was revised in November 2020, and a new flow diagram with recommendations for initial immunomodulatory treatment of MIS-C was added. CONCLUSION: Our understanding of SARS-CoV-2-related syndromes in the pediatric population continues to evolve. This guidance document reflects currently available evidence coupled with expert opinion, and will be revised as further evidence becomes available.
引用
- Henderson LA, Canna SW, Friedman KG, et al. American College of Rheumatology Clinical Guidance for Multisystem Inflammatory Syndrome in Children Associated With SARS-CoV-2 and Hyperinflammation in Pediatric COVID-19: Version 2. Arthritis Rheumatol. 2021. PMID: 33277976. doi:10.1002/art.41616
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。